UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway
Yang Wang,Ge Gao,Xiangpin Wei,Yang Zhang,Jian Yu
DOI: https://doi.org/10.2147/dddt.s405450
2023-05-05
Abstract:Yang Wang, Ge Gao, Xiangpin Wei, Yang Zhang, Jian Yu Department of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China Correspondence: Jian Yu, Department of Neurosurgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Tel + 86 551 62283413, Fax + 86 551 62283413, Email Purpose: Patients with glioblastoma (GBM) have poor prognosis and limited therapeutic options, largely because of chemoresistance to temozolomide (TMZ) treatment. Ubiquitin conjugating enzyme E2 T (UBE2T) plays a key role in regulating the malignancy of various tumors, including GBM; however, its role in TMZ resistance of GBM has not been elucidated. The purpose of this study was to clarify the role of UBE2T in mediating TMZ resistance and investigate the specific underlying mechanism. Methods: Western blotting was used to detect the protein levels of UBE2T and Wnt/β-catenin-related factors. CCK-8, flow cytometry, and colony formation assays were used to examine the effect of UBE2T on TMZ resistance. Wnt/β-catenin signaling pathway activation was inhibited using XAV-939, and a xenograft mouse model was generated to clarify the function of TMZ in vivo. Results: UBE2T knockdown sensitized GBM cells to TMZ treatment, whereas UBE2T overexpression promoted TMZ resistance. The specific UBE2T inhibitor, M435-1279, increased the sensitivity of GBM cells to TMZ. Mechanistically, our results demonstrated that UBE2T induces β-catenin nuclear translocation and increases the protein levels of downstream molecules, including survivin and c-Myc. Inhibition of Wnt/β-catenin signaling using XAV-939 blocked TMZ resistance due to UBE2T overexpression in GBM cells. In addition, UBE2T was shown to facilitate TMZ resistance by inducing Wnt/β-catenin signaling pathway activation in a mouse xenograft model. Combined treatment with TMZ and UBE2T inhibitor achieved superior tumor growth suppression relative to TMZ treatment alone. Conclusion: Our data reveal a novel role of UBE2T in mediating TMZ resistance of GBM cells via regulating Wnt/β-catenin signaling. These findings indicate that targeting UBE2T has promising potential to overcome TMZ resistance of GBM. Keywords: glioblastoma, temozolomide, drug resistance, UBE2T, Wnt/β-catenin Glioblastoma (GBM) is the most common malignant primary brain tumor and is associated with higher recurrence and lower survival rates. 1,2 Temozolomide (TMZ)-based chemotherapies are the standard treatment options for GBM; 3 however, GBM tumors inevitably become resistant to TMZ and patients have poor prognosis, due to the molecular heterogeneity, hyperactivation of pro-survival pathways, rapid growth rate, and immunosuppression of GBM tumors. 4 Aberrantly activated genes, such as O6-methylguanine-DNA methyltransferase ( MGMT ), which can repair DNA alkylation damage caused by TMZ, have key roles in TMZ resistance of GBM. 5 Although there have been many attempts to improve the efficacy of therapy for GBM, unfortunately, none have achieved the desired therapeutic effect. 6 Therefore, it is of great clinical significance to elucidate the mechanism underlying TMZ resistance and develop new targets for therapeutic intervention. Ubiquitin conjugating enzyme E2 T (UBE2T, also known as HSPC150) belongs to the ubiquitin E2 family and participates in ubiquitin activation by transfer from the E1 activating enzyme to the substrate. 7 UBE2T was initially reported as a negative regulator of the Fanconi anemia (FA) pathway; its deletion leads to impaired DNA repair ability and the formation of abnormal chromosomes, which are a feature of FA. 8,9 In addition to its relevance in FA, UBE2T also has vital roles in the development, progression, and recurrence of various tumors. 10–14 UBE2T facilitates the occurrence and development of ovarian cancer by regulating epithelial–mesenchymal transition (EMT) through the PI3K-AKT pathway. 15 Further, silencing of UBE2T represses lung adenocarcinoma progression by increasing the expression of fibulin 5, 16 and UBE2T can also promote pyrimidine metabolism by enhancing Akt K63-linked ubiquitination, thus contributing to hepatocellular carcinoma (HCC) development. 17 Recent studies have discovered that UBE2T plays a key role in therapy resistance in various tumors. For example, UBE2T enhances radiation resistance through ubiquitination-mediated FOXO1 degradation and Wnt/β-catenin signaling pathway activation in non-small cell lung cancer. 18 Further, UBE2T-mediated mono-ubiquitination of H2AX/γH2AX decrease -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal